---
title: "Eliquis (apixaban) in nonvalvular atrial fibrillation: Clinical trials questions"
description: "Clinical trials questions on Eliquis (apixaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: ARISTOTLE trial and AVERROES trial. Questions: Eliquis vs warfarin: how was the ARISTOTLE trial designed? Is Eliquis better than warfarin at preventing stroke in atrial fibrillation (ARISTOTLE)? Does Eliquis cause less major bleeding than warfarin (ARISTOTLE)? Does Eliquis cause less intracranial or fatal bleeding than warfarin (ARISTOTLE)? 5 further questions follow. 9 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Eliquis (apixaban) in nonvalvular atrial fibrillation: Clinical trials questions

Manufacturer: Bristol-Myers Squibb Company; Pfizer Inc  
Prescribing information: [Eliquis](https://packageinserts.bms.com/pi/pi_eliquis.pdf)

## ARISTOTLE trial

<a id="eliquis-aristotle-design"></a>

### Eliquis vs warfarin: how was the ARISTOTLE trial designed?

> “A pivotal, phase III, randomized, double-blind clinical trial designed to compare the effects of ELIQUIS 5 mg twice daily<sup>‡</sup> (n=9120) and warfarin (n=9081) (target international normalized ratio [INR] range: 2.0–3.0) in reducing the risk of stroke and systemic embolism (SE) in 18,201 patients with NVAF and ≥1 risk factors for stroke: prior stroke or transient ischemic attack (TIA), prior SE, ≥75 years of age, arterial hypertension requiring treatment, diabetes mellitus, heart failure ≥New York Heart Association (NYHA) Class 2, or decreased left ventricular ejection fraction (LVEF) ≤40%.<sup>1-3</sup>
>
> Patients were followed for a median of ≈1.7 years. The 2 treatment groups were well balanced with respect to baseline characteristics, including age, stroke risk (CHADS2 score),<sup>§</sup> and prior vitamin K antagonist (VKA) experience.<sup>2</sup>
>
> The primary efficacy endpoint was stroke/systemic embolism, and the primary safety endpoint was major bleeding.<sup>1</sup>”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=A%20pivotal%2C%20phase%20III%2C%20randomized%2C,primary%20safety%20endpoint%20was%20major)

> “A dose of 2.5 mg twice daily was assigned to patients with at least 2 of the following characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=A%20dose%20of%202.5%20mg,or%20serum%20creatinine%20%E2%89%A51.5%20mg%2FdL.)

<a id="eliquis-aristotle-stroke"></a>

### Is Eliquis better than warfarin at preventing stroke in atrial fibrillation (ARISTOTLE)?

> “A total of 18,201 patients were randomized and followed on study treatment for a median of 
> 89 weeks.”

Source: [ELIQUIS: Prescribing information, page 9, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=9)

> “ELIQUIS was superior to warfarin for the primary endpoint of reducing the risk of stroke and 
> systemic embolism (Table 13 and Figure 4). Superiority to warfarin was primarily attributable to a 
> reduction in hemorrhagic stroke and ischemic strokes with hemorrhagic conversion compared 
> to warfarin. Purely ischemic strokes occurred with similar rates on both drugs.”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

> “Table 13: 	
> Key Efficacy Outcomes in Patients with Nonvalvular Atrial Fibrillation in 
> ARISTOTLE (Intent-to-Treat Analysis)
> ELIQUIS 
> N=9120 
> n (%/year)
> Warfarin 
> N=9081 
> n (%/year)
> Hazard Ratio 
> (95% CI)
> P-value
> Stroke or systemic embolism
> 212 (1.27)
> 265 (1.60)
> 0.79 (0.66, 0.95)
> 0.01
>
> Stroke
> 199 (1.19)
> 250 (1.51)
> 0.79 (0.65, 0.95)
>
> 	 Ischemic without hemorrhage
> 140 (0.83)
> 136 (0.82)
> 1.02 (0.81, 1.29)
>
> 	 Ischemic with hemorrhagic 
> conversion
> 12 (0.07)
> 20 (0.12)
> 0.60 (0.29, 1.23)
>
> 	 Hemorrhagic
> 40 (0.24)
> 78 (0.47)
> 0.51 (0.35, 0.75)
>
> 	 Unknown
> 14 (0.08)
> 21 (0.13)
> 0.65 (0.33, 1.29)
>
> Systemic embolism
> 15 (0.09)
> 17 (0.10)
> 0.87 (0.44, 1.75)
> The primary endpoint was based on the time to first event (one per subject). Component counts 
> are for subjects with any event, not necessarily the first.”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

<a id="eliquis-aristotle-major-bleeding"></a>

### Does Eliquis cause less major bleeding than warfarin (ARISTOTLE)?

> “Table 2:	
> Bleeding Events in Patients with Nonvalvular Atrial Fibrillation  
> in ARISTOTLE*
> ELIQUIS 
> N=9088 
> n (per  
> 100 pt-year)
> Warfarin 
> N=9052 
> n (per  
> 100 pt-year)
> Hazard Ratio 
> (95% CI)
> P-value
> Major<sup>†</sup>
> 327 (2.13)
> 462 (3.09)
> 0.69 (0.60, 0.80)
> <0.0001”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

> “Bleeding events within each subcategory were counted once per subject, but subjects may have 
> contributed events to multiple endpoints. Bleeding events were counted during treatment or within 
> 2 days of stopping study treatment (on-treatment period).
> <sup>†</sup>	Defined as clinically overt bleeding accompanied by one or more of the following: a decrease 
> in hemoglobin of ≥2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at 
> a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with 
> compartment syndrome, retroperitoneal or with fatal outcome.”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

> “ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=ELIQUIS%20increases%20the%20risk%20of,cause%20serious%2C%20potentially%20fatal%2C%20bleeding.)

<a id="eliquis-aristotle-intracranial-bleeding"></a>

### Does Eliquis cause less intracranial or fatal bleeding than warfarin (ARISTOTLE)?

> “There were significantly fewer ICH events vs warfarin. Hemorrhagic stroke<sup>#</sup>: 0.24%/yr (n=38/9088) vs 0.49%/yr (n=74/9052), HR=0.51 (95% CI: 0.34-0.75); other ICH: 0.10%/yr (n=15/9088) vs 0.34%/yr (n=51/9052), HR=0.29 (95% CI: 0.16-0.51)<sup>1</sup>
>  There were significantly fewer fatal bleeding events vs warfarin. Intracranial: 0.03%/yr (n=4/9088) vs 0.20%/yr (n=30/9052), HR=0.13 (95% CI: 0.05-0.37); nonintracranial: 0.04%/yr (n=6/9088) vs 0.05%/yr (n=7/9052), HR=0.84 (95% CI: 0.28-2.15)<sup>1</sup>”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=There%20were%20significantly%20fewer%20ICH,0.05%25%2Fyr%20%28n%3D7%2F9052%29%2C%20HR%3D0.84%20%2895%25%20CI%3A)

> “On-treatment analysis based on the safety population, compared to intent-to-treat analysis presented in efficacy population.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=On%2Dtreatment%20analysis%20based%20on%20the,analysis%20presented%20in%20efficacy%20population.)

> “Table 2:	
> Bleeding Events in Patients with Nonvalvular Atrial Fibrillation  
> in ARISTOTLE*
> ELIQUIS 
> N=9088 
> n (per  
> 100 pt-year)
> Warfarin 
> N=9052 
> n (per  
> 100 pt-year)
> Hazard Ratio 
> (95% CI)
> P-value
> Major<sup>†</sup>
> 327 (2.13)
> 462 (3.09)
> 0.69 (0.60, 0.80)
> <0.0001
> 	 Intracranial (ICH)<sup>‡</sup>
> 52 (0.33)
> 125 (0.82)
> 0.41 (0.30, 0.57)
> -
> 	 Hemorrhagic stroke<sup>§</sup>
> 38 (0.24)
> 74 (0.49)
> 0.51 (0.34, 0.75)
> -
> 	 Other ICH
> 15 (0.10)
> 51 (0.34)
> 0.29 (0.16, 0.51)
> -
> 	 Gastrointestinal (GI)<sup>¶</sup>
> 128 (0.83)
> 141 (0.93)
> 0.89 (0.70, 1.14)
> -
> 	 Fatal <sup>#</sup>
> 10 (0.06)
> 37 (0.24)
> 0.27 (0.13, 0.53)
> -”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

<a id="eliquis-aristotle-mortality"></a>

### Did Eliquis lower the risk of death compared with warfarin in ARISTOTLE?

> “All-cause death was assessed using a sequential testing strategy that allowed testing for 
> superiority if effects on earlier endpoints (stroke plus systemic embolus and major bleeding) 
> were demonstrated. ELIQUIS treatment resulted in a significantly lower rate of all-cause death 
> (p = 0.046) than did treatment with warfarin, primarily because of a reduction in cardiovascular 
> death, particularly stroke deaths. Non-vascular death rates were similar in the treatment arms.”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

> “Cardiovascular deaths (1.80%/year vs 2.02%/year, HR=0.89 [95% CI: 0.76–1.04]), particularly stroke deaths (0.42% vs 0.72%), were the greatest contributors to the reduction in all-cause mortality vs warfarin<sup>2,4</sup>
>  The incidence of nonvascular mortality was similar in patients taking ELIQUIS to that in patients taking warfarin (1.14%/year vs 1.22%/year, HR=0.93 [95% CI: 0.77–1.13])<sup>2</sup>”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Cardiovascular%20deaths%20%281.80%25%2Fyear%20vs%202.02%25%2Fyear%2C,vs%201.22%25%2Fyear%2C%20HR%3D0.93%20%5B95%25%20CI%3A)

<a id="eliquis-aristotle-subgroups"></a>

### Were Eliquis results consistent across patient subgroups in ARISTOTLE?

> “In ARISTOTLE, the results for the primary efficacy endpoint were generally consistent across 
> most major subgroups including weight, CHADS2 score (a scale from 0 to 6 used to predict 
> risk of stroke in patients with AF, with higher scores predicting greater risk), prior warfarin 
> use, level of renal impairment, geographic region, and aspirin use at randomization (Figure 5).”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

> “In ARISTOTLE, the results for major bleeding were generally consistent across most major 
> subgroups including age, weight, CHADS2 score (a scale from 0 to 6 used to estimate risk 
> of stroke, with higher scores predicting greater risk), prior warfarin use, geographic region, 
> and aspirin use at randomization (Figure 1). Subjects treated with ELIQUIS with diabetes 
> bled more (3% per year) than did subjects without diabetes (1.9% per year).”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

> “Patients with diabetes who were treated with ELIQUIS bled more than patients without diabetes (3.0%/year vs 1.9%/year, respectively). Major bleeds were observed in ELIQUIS and warfarin patients with diabetes at a rate of 3.0%/year and 3.1%/year, respectively.”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Patients%20with%20diabetes%20who%20were,of%203.0%25%2Fyear%20and%203.1%25%2Fyear%2C%20respectively.)

> “Note: The figure above presents effects in various subgroups, all of which are baseline characteristics and all of which were prespecified, if not the groupings. The 95% confidence limits that are shown 
> do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should 
> not be over-interpreted.”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

<a id="eliquis-aristotle-renal-function"></a>

### Were Eliquis results in ARISTOTLE consistent in patients with reduced kidney function?

> “Generally consistent efficacy across levels of renal function in ARISTOTLE in the reduction of the risk of stroke/systemic embolism<sup>1,2</sup>
>
> Results from a prespecified subgroup analysis<sup>††</sup> of NVAF patients
>  Patients with a serum creatinine level of >2.5 mg/dL or calculated creatinine clearance of <25 mL/min were excluded from the ARISTOTLE trial<sup>2</sup>
>  In the ARISTOTLE trial, 5319 patients in the ELIQUIS arm had various levels of renal impairment<sup>1</sup>”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Generally%20consistent%20efficacy%20across%20levels,had%20various%20levels%20of%20renal)

> “Stroke and Systemic Embolism Hazard Ratios by Baseline Characteristics”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

> “n of Events / N of Patients (% per year)
> Subgroup
> Apixaban
> Warfarin
> Hazard Ratio (95% CI)”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

> “Creatinine Clearance
> <30 mL/min (1%)
> 6 / 137 (2.8)
> 10 / 133 (5.1)
> 0.55 (0.20, 1.53)
> 30-50 mL/min (15%)
> 48 / 1365 (2.0)
> 59 / 1382 (2.5)
> 0.83 (0.57, 1.21)
> >50-80 mL/min (42%)
> 87 / 3817 (1.2)
> 116 / 3770 (1.7)
> 0.74 (0.56, 0.97)
> >80 mL/min (41%)
> 70 / 3761 (1.0)
> 79 / 3757 (1.1)
> 0.88 (0.64, 1.21)”

Source: [ELIQUIS: Prescribing information, page 10, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=10)

> “Major Bleeding Hazard Ratios by Baseline Characteristics”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

> “n of Events / N of Patients (% per year)
> Subgroup
> Apixaban
> Warfarin
> Hazard Ratio (95% CI)”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

> “Creatinine Clearance
> <30 mL/min (1%)
> 7 / 136 (3.7)
> 19 / 132 (11.9)
> 0.32 (0.13, 0.78)
> 30-50 mL/min (15%)
> 66 / 1357 (3.2)
> 123 / 1380 (6.0)
> 0.53 (0.39, 0.71)
> >50-80 mL/min (42%)
> 157 / 3807 (2.5)
> 199 / 3758 (3.2)
> 0.76 (0.62, 0.94)
> >80 mL/min (41%)
> 96 / 3750 (1.5)
> 119 / 3746 (1.8)
> 0.79 (0.61, 1.04)”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

> “Note: The figures above present effects in one of various subgroups, all of which are baseline characteristics and all of which were prespecified, if not the groupings. The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.<sup>1</sup>”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=Note%3A%20The%20figures%20above%20present,among%20groups%20should%20not%20be)

## AVERROES trial

<a id="eliquis-averroes-efficacy"></a>

### Is Eliquis more effective than aspirin at preventing stroke when warfarin is unsuitable (AVERROES)?

> “In AVERROES, patients with nonvalvular atrial fibrillation thought not to be candidates 
> for warfarin therapy were randomized to treatment with ELIQUIS 5 mg orally twice daily 
> (or 2.5 mg twice daily in selected patients) or aspirin 81 to 324 mg once daily. The primary 
> objective of the study was to determine if ELIQUIS was superior to aspirin for preventing the 
> composite outcome of stroke or systemic embolism. AVERROES was stopped early on the 
> basis of a prespecified interim analysis showing a significant reduction in stroke and systemic 
> embolism for ELIQUIS compared to aspirin that was associated with a modest increase in major 
> bleeding (Table 14) [see Adverse Reactions (6.1)].”

Source: [ELIQUIS: Prescribing information, page 11, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=11)

> “Table 14:	
> Key Efficacy Outcomes in Patients with Nonvalvular Atrial Fibrillation in 
> AVERROES
> ELIQUIS 
> N=2807 
> n (%/year)
> Aspirin 
> N=2791 
> n (%/year)
> Hazard Ratio 
> (95% CI)
> P-value
> Stroke or systemic embolism
> 51 (1.62)
> 113 (3.63)
> 0.45 (0.32, 0.62)
> <0.0001
>
> Stroke
>
> 	 Ischemic or 
>
> 	 	 undetermined
> 43 (1.37)
> 97 (3.11)
> 0.44 (0.31, 0.63)
> -
>
> 	 Hemorrhagic
> 6 (0.19)
> 9 (0.28)
> 0.67 (0.24, 1.88)
> -
>
> Systemic embolism
> 2 (0.06)
> 13 (0.41)
> 0.15 (0.03, 0.68)
> -
> MI
> 24 (0.76)
> 28 (0.89)
> 0.86 (0.50, 1.48)
> -
> All-cause death
> 111 (3.51)
> 140 (4.42)
> 0.79 (0.62, 1.02)
> 0.068
>
> Vascular death
> 84 (2.65)
> 96 (3.03)
> 0.87 (0.65, 1.17)
> -”

Source: [ELIQUIS: Prescribing information, page 11, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=11)

<a id="eliquis-averroes-bleeding"></a>

### Did Eliquis increase major bleeding compared with aspirin in AVERROES?

> “In another clinical trial (AVERROES), ELIQUIS was associated with an increase in major bleeding compared with aspirin that was not statistically significant (1.41%/year vs 0.92%/year, HR=1.54 [95% CI: 0.96–2.45]; P=0.07)”

Source: [ELIQUIS: NVAF Stroke Risk Efficacy & Safety Data, captured 2026-11-12](https://www.eliquis.com/eliquis/hcp/efficacy-safety/nvaf#:~:text=In%20another%20clinical%20trial%20%28AVERROES%29%2C,HR%3D1.54%20%5B95%25%20CI%3A%200.96%E2%80%932.45%5D%3B%20P%3D0.07%29)

> “Table 3:	
> Bleeding Events in Patients with Nonvalvular Atrial Fibrillation 
> in AVERROES 
> ELIQUIS
> N=2798
> n (%/year)
> Aspirin
> N=2780
> n (%/year)
> Hazard Ratio 
> (95% CI)
> P-value
> Major
> 45 (1.41)
> 29 (0.92)
> 1.54 (0.96, 2.45)
> 0.07
>
> Fatal
> 5 (0.16)
> 5 (0.16)
> 0.99 (0.23, 4.29)
> -
>
> Intracranial
> 11 (0.34)
> 11 (0.35)
> 0.99 (0.39, 2.51)
> -
> Events associated with each endpoint were counted once per subject, but subjects may have 
> contributed events to multiple endpoints.”

Source: [ELIQUIS: Prescribing information, page 5, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=5)

> “In AVERROES, the mean duration of 
> exposure was approximately 59 weeks (>3000 patient-years).”

Source: [ELIQUIS: Prescribing information, page 4, captured 2026-11-12](https://packageinserts.bms.com/pi/pi_eliquis.pdf#page=4)

## Related pages
- [Medical information: Eliquis (apixaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/pharmacology)
- [Real-world evidence](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/safety)
- [Specific populations](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/eliquis--nonvalvular-atrial-fibrillation/access-and-coverage)
